All In Biotech

Drug Trial Radar · NCT02180100

Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe

Last checked: Nov 19, 2026Latest source record: Oct 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 2013

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Peking University Shenzhen HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Shyndec Pharmaceutical Co., Ltd.
First posted
Jul 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 48 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.

Conditions

  • Vulvovaginal Candidiasis

Interventions

  • Terconazole Vaginal SuppositoryDrug

    Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days

  • FluconazoleDrug

    orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mycological Cure 1Time frame: Between day 7-14 after treatment, an average of 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hosptal

    Shenzhen, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.